New hope for heart patients: pelacarsen available through special program
NCT ID NCT07000695
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides access to pelacarsen, a drug for atherosclerotic cardiovascular disease, for patients who have no other treatment options and cannot join a clinical trial. It is for those with serious or life-threatening conditions where the potential benefit outweighs the risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pelacarsen
- What this could lead to
- If successful, this program could provide access to a new treatment option for patients with serious heart disease who have no other alternatives.
- What could go wrong
- This is not a clinical trial but a managed access program, so data on effectiveness and safety is limited. The drug may not work for everyone and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drop of blood predict disease years before it strikes?
- Can a cheap arthritis drug shield kidneys from heart and bone damage?
- Can extremely low cholesterol save more hearts? new trial aims to find out
- Double-Drug attack on cholesterol: could two be better than one?
- Could a Half-Dose of aspirin protect elderly hearts just as well?
- AI spots hidden heart risk in old scans, prompts better treatment